Preoperative IV iron modestly reduced transfusion in anemic cardiac-surgery patients
AI-summarized from the linked source. Educational brief, not medical advice.
Brief summary
In an international randomized trial of 955 adults with anemia before elective cardiac surgery, preoperative intravenous iron reduced in-hospital red-cell transfusion and produced a small improvement in days alive and at home by day 90.
What NurseJet pulled from the source
Red-cell transfusion occurred in 61.1% of the intravenous-iron group and 68.2% of the placebo group (relative risk 0.90, 95% CI 0.82 to 0.99). Median days alive and at home were 81.1 versus 80.0, an adjusted one-day difference; major complications and hospital stay did not differ.
Why this matters for nurses
Cardiac and perioperative nurses help identify preoperative anemia, administer prescribed iron, coordinate laboratory follow-up, and monitor transfusion needs. The trial supports intravenous iron as one blood-management component while keeping the absolute clinical gain and unchanged complication findings visible.
Bedside takeaway
Preoperative IV iron reduced transfusion modestly and added about one day alive at home by day 90, without changing major complications or length of stay.
How This Applies in Practice
Use this when: Preparing an anemic adult for elective cardiac surgery within a clinician-directed patient-blood-management pathway.
On your shift
- Confirm the ordered iron formulation, dose, timing, eligibility review, laboratory data, and infusion-monitoring requirements.
- Document administration and any reaction using the medication-safety pathway, and communicate whether follow-up testing is complete before surgery.
- Continue the ordered postoperative bleeding, hemoglobin, and transfusion surveillance rather than assuming preoperative iron removes transfusion risk.
Key takeaways
- The double-blind trial enrolled 955 adults across 33 hospitals in 10 countries before elective cardiac surgery.
- Participants received 1000 mg intravenous iron or placebo 1 to 26 weeks before surgery.
- In-hospital red-cell transfusion was less frequent with intravenous iron, with a relative risk of 0.90.
- The adjusted improvement in days alive and at home was one day, with no detected difference in major complications or hospital length of stay.
Practice implications
- For a patient enrolled in a preoperative anemia pathway, verify the ordered iron formulation, dose, timing, required laboratory data, and infusion-monitoring steps. Continue standard postoperative bleeding and transfusion surveillance; preoperative treatment does not eliminate the need for individualized blood-management decisions.
Limitations & cautions
- The primary outcome difference was small, transfusion remained common in both groups, and the trial found no difference in major complications or hospital stay. Results apply to anemic adults undergoing elective cardiac surgery and do not establish benefit for emergency surgery or patients meeting the trial's exclusions.
- AI-summarized from the linked source. Review the original article before applying to practice.
Citations
Exact source links
Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.
BMJ (Clinical research ed.) (PubMed)
BMJ (Clinical research ed.) (PubMed). Intravenous iron to treat anaemia before cardiac surgery (ITACS): international, double blind, placebo controlled randomised trial.
https://pubmed.ncbi.nlm.nih.gov/42618081/
Professional education only
